New hope for breast cancer patients who stopped responding to standard therapy
NCT ID NCT07182721
First seen Jun 26, 2026 · Last updated Jul 16, 2026 · Updated 2 times
Summary
This phase 2 trial tests a combination of two drugs, SKB264 and inetetamab, in 48 adults with HER2-positive advanced breast cancer that has worsened after prior treatment with T-DXd. The goal is to see if the combo can shrink tumors. Participants receive the drugs intravenously every two weeks. The study is single-center and single-arm, meaning everyone gets the same treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SKB264 (a chemotherapy drug) plus inetetamab (a targeted antibody therapy)
- What this could lead to
- If this works, it could offer a new treatment option for people with HER2-positive advanced breast cancer who have stopped responding to current therapies.
- What could go wrong
- This is a small, early-phase trial with only 48 participants and no comparison group, so results may not apply broadly. The combination may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China